Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 271,866 shares, a growth of 715.0% from the August 31st total of 33,356 shares. Based on an average daily volume of 20,006,870 shares, the short-interest ratio is currently 0.0 days. Currently, 26.5% of the shares of the company are short sold.
Biodexa Pharmaceuticals Trading Down 2.1%
BDRX stock traded down $0.01 on Thursday, reaching $0.68. 126,594 shares of the company’s stock were exchanged, compared to its average volume of 10,626,635. The stock has a fifty day moving average of $1.23 and a 200-day moving average of $2.61. Biodexa Pharmaceuticals has a twelve month low of $0.61 and a twelve month high of $59.40.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, September 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Biodexa Pharmaceuticals has an average rating of “Sell”.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC acquired a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals comprises about 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th largest holding. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals as of its most recent SEC filing. Institutional investors own 17.51% of the company’s stock.
Biodexa Pharmaceuticals Company Profile
Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company combines drug candidates with proprietary delivery technologies intended to improve how therapies are administered, distributed, or released in the body.
Biodexa’s pipeline has included MTX110, a liquid formulation of the cancer medicine panobinostat being investigated for direct administration into brain tumors, including diffuse midline glioma.
Featured Stories
- Five stocks we like better than Biodexa Pharmaceuticals
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Biodexa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodexa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
